Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Cash Flow: 2019-2023

Historic Net Cash Flow for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2023 value amounting to -$32.0 million.

  • ADC Therapeutics' Net Cash Flow rose 77.14% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$48.0 million, marking a year-over-year increase of 65.67%. This contributed to the annual value of -$27.6 million for FY2024, which is 42.43% up from last year.
  • Latest data reveals that ADC Therapeutics reported Net Cash Flow of -$32.0 million as of Q4 2023, which was up 13.58% from -$37.0 million recorded in Q3 2023.
  • In the past 5 years, ADC Therapeutics' Net Cash Flow registered a high of $36.9 million during Q2 2023, and its lowest value of -$139.8 million during Q4 2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$44,770 (2022), whereas its average is -$13.4 million.
  • Examining YoY changes over the last 5 years, ADC Therapeutics' Net Cash Flow showed a top increase of 68,499.10% in 2023 and a maximum decrease of 859,017.79% in 2023.
  • Quarterly analysis of 5 years shows ADC Therapeutics' Net Cash Flow stood at -$24.2 million in 2019, then reached -$33.2 million in 2020, then skyrocketed by 99.83% to $27.3 million in 2021, then slumped by 613.03% to -$139.8 million in 2022, then skyrocketed by 77.14% to -$32.0 million in 2023.
  • Its last three reported values are -$32.0 million in Q4 2023, -$37.0 million for Q3 2023, and $36.9 million during Q2 2023.